Key Highlights
- IRIDEX (NASDAQ:IRIX) reported third-quarter Revenue of USD 10.2 million, down 18.6% from USD 12.5 million a year earlier.
- Gross Margin rose to 42.4% from 32.1%, helped by cost reduction work and a move to lower cost contract manufacturers.
- The net loss narrowed to USD 1.4 million, or USD 0.08 per share, from USD 1.6 million in the same quarter of 2025.
- Cash and cash equivalents were USD 3.7 million at October 3, 2026, compared with USD 6.0 million at the start of the fiscal year.
Margin Gains Offset a Steep Quarterly Revenue Decline
IRIDEX (NASDAQ:IRIX) filed its Quarterly Report for the period ended October 3, 2026, showing revenue of USD 10.2 million against USD 12.5 million a year earlier, a drop of 18.6%. The company attributes the decline to macroeconomic conditions and to customer purchases that were pulled forward into an earlier period of fiscal 2026. Sales fell across all of its product groups, and within that mix, the retina category was down 23.6%.
The company develops laser systems and delivery devices used by eye surgeons, with products for glaucoma and retinal disease. Its Cyclo G6 glaucoma system is the growth product in the portfolio, while retina lasers remain the largest revenue group.
Gross Margin Expands Ten Points on Lower Manufacturing Costs
Gross profit rose 7.2% to USD 4.3 million from USD 4.0 million even though sales were lower. Gross margin climbed to 42.4% from 32.1%. The filing credits cost reduction initiatives, including the continued shift to contract manufacturers with lower costs, partly offset by higher product costs tied to tariffs.
Research and development spending was flat at about USD 1.0 million, which the filing links to continued cost saving and lower spending on new product investments. Sales and Marketing expense fell 9.4% to USD 2.4 million, while general and administrative expense rose 13.8% to USD 2.0 million, mostly because of the corporate office move from Mountain View to San Jose in California.
Nine-Month Results Show Glaucoma Growth and a Tighter Cash Position
Over nine months, revenue declined 9.0% to USD 34.5 million from USD 38.0 million. Cyclo G6 sales increased 7.1% to USD 10.7 million, retina revenue slid 18.5% to USD 17.4 million, and other products slipped 2.8% to USD 6.4 million. The nine-month net loss narrowed to USD 3.2 million from USD 4.3 million.
Cash and cash equivalents were USD 3.7 million at quarter end, and Working Capital was USD 9.8 million compared with USD 12.0 million at the beginning of the year. Operating Activities used USD 2.1 million of cash over nine months, against USD 2.7 million a year earlier, and the accumulated Deficit stood at about USD 95.6 million. The cover page lists 17,807,470 shares outstanding as of November 11, 2026.
Where Things Stand
Margin improved sharply, but the sales line moved the other way. IRIDEX (NASDAQ:IRIX) grew gross margin by 10.3 points, narrowed its quarterly loss and cut operating cash use, yet revenue fell 18.6% in the quarter and cash dropped to USD 3.7 million. Calculated from the filing, nine-month operating cash use of USD 2.1 million implies about 16 months of cover for the USD 3.7 million balance at that pace. Upcoming filings will show whether the company can repeat the margin gain on a smaller sales base, whether the lower cost base holds, and whether capital spending at hospitals, surgical centers and physician offices recovers.






Please wait processing your request...